blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3544613

EP3544613 - GSK-3 INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.04.2022
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  10.05.2021
FormerGrant of patent is intended
Status updated on  21.12.2020
FormerRequest for examination was made
Status updated on  30.08.2019
FormerThe international publication has been made
Status updated on  13.06.2018
Formerunknown
Status updated on  21.12.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2019/40]
Inventor(s)01 / HARTZ, Richard A.
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
02 / AHUJA, Vijay T.
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
03 / LUO, Guanglin
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
04 / CHEN, Ling
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
05 / SIVAPRAKASAM, Prasanna
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
06 / DUBOWCHIK, Gene M.
65 Spring Street
Middlefield, Connecticut 06455 / US
07 / JACUTIN-PORTE, Swanee E.
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
08 / MACOR, John E.
55 Commanders Drive
Washington Crossing, Pennsylvania 18977 / US
 [2019/40]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2021/23]
Former [2019/40]Kling, Edouard
Swords Laboratories, Ireland
Swiss Branch, Steinhausen
Hinterbergstrasse 16
6312 Steinhausen / CH
Application number, filing date17812188.527.11.2017
[2019/40]
WO2017US63231
Priority number, dateUS201662426631P28.11.2016         Original published format: US 201662426631 P
[2019/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018098412
Date:31.05.2018
Language:EN
[2018/22]
Type: A1 Application with search report 
No.:EP3544613
Date:02.10.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 31.05.2018 takes the place of the publication of the European patent application.
[2019/40]
Type: B1 Patent specification 
No.:EP3544613
Date:09.06.2021
Language:EN
[2021/23]
Search report(s)International search report - published on:EP31.05.2018
ClassificationIPC:A61K31/506, C07D403/12, A61P25/00
[2019/40]
CPC:
A61P25/00 (EP); C07D401/12 (EP,KR,US); A61K31/506 (KR);
A61P25/28 (KR,US); C07D239/42 (KR); C07D401/14 (EP,KR,US);
C07D403/12 (EP,KR,US); C07D405/14 (EP,KR,US); C07D417/14 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/40]
Extension statesBANot yet paid
MENot yet paid
Validation statesMA04.06.2019
MD04.06.2019
TitleGerman:GSK-3-INHIBITOREN[2019/40]
English:GSK-3 INHIBITORS[2019/40]
French:INHIBITEURS DE GSK-3[2019/40]
Entry into regional phase04.06.2019National basic fee paid 
04.06.2019Designation fee(s) paid 
04.06.2019Examination fee paid 
Examination procedure04.06.2019Examination requested  [2019/40]
04.06.2019Date on which the examining division has become responsible
23.01.2020Amendment by applicant (claims and/or description)
22.12.2020Communication of intention to grant the patent
28.04.2021Fee for grant paid
28.04.2021Fee for publishing/printing paid
28.04.2021Receipt of the translation of the claim(s)
Opposition(s)10.03.2022No opposition filed within time limit [2022/20]
Fees paidRenewal fee
04.06.2019Renewal fee patent year 03
13.11.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.11.2017
AL09.06.2021
AT09.06.2021
CY09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
MK09.06.2021
MT09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
[2024/42]
Former [2024/23]HU27.11.2017
AL09.06.2021
AT09.06.2021
CY09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
MK09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
Former [2023/33]HU27.11.2017
AL09.06.2021
AT09.06.2021
CY09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
Former [2023/30]AL09.06.2021
AT09.06.2021
CY09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
Former [2022/48]AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
IE27.11.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
Former [2022/37]AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
LU27.11.2021
BE30.11.2021
CH30.11.2021
LI30.11.2021
Former [2022/34]AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
LU27.11.2021
BE30.11.2021
Former [2022/33]AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
BE30.11.2021
Former [2022/29]AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/26]AL09.06.2021
AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/21]AT09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/10]AT09.06.2021
CZ09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/09]AT09.06.2021
CZ09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
RO09.06.2021
RS09.06.2021
SE09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
PT11.10.2021
Former [2022/07]AT09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
NL09.06.2021
RS09.06.2021
SE09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
Former [2021/51]FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
RS09.06.2021
SE09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
Former [2021/49]FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
SE09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
Former [2021/47]FI09.06.2021
LT09.06.2021
BG09.09.2021
Former [2021/46]FI09.06.2021
LT09.06.2021
Cited inInternational search[X]WO2009014637  (SCHERING CORP [US], et al) [X] 1-10 * page 131 - page 133; table 10; compounds 257-260, 262, 267 *;
 [AD]WO2015069594  (BRISTOL MYERS SQUIBB CO [US]) [AD] 1-10* example -; claim - *
by applicantWO2015069594
    - Immunity, (20160216), vol. 44, no. 2
    - WOODGETT JR, "GSK-3: functional insights from cell biology and animal models", Front. Mol. Neurosci., (20110000), vol. 4, page 40
    - GENTLES, RG; HU, S; DUBOWCHIK, GM, "Recent Advances in the Discovery of GSK-3 Inhibitors and a Perspective on their Utility for the Treatment of Alzheimer's Disease", Annual Reports in Medicinal Chemistry, (20090000), vol. 44, pages 3 - 26
    - HARTZ et al., Bioorg. Med. Chem. Lett., (20100000), vol. 20, pages 1890 - 1894
    - HARTZ et al., J. Med. Chem., (20090000), vol. 52, pages 7653 - 7668
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.